TY - T1的脑萎缩和代谢减退的进展存在β-amyloidosis轻度认知障碍(S41.007) JF -神经学乔-神经学六世- 84 - 14补充SP - S41.007盟David Knopman AU -克利福德杰克AU -艾米丽Lundt盟-希瑟Wiste AU -斯蒂芬We首页igand盟Prashanthi Vemuri AU - Val劳盟Kejal Kantarci AU -杰弗里·冈特盟马修Senjem AU -米歇尔Mielke盟玫瑰花蕾罗伯茨AU -布拉德利Boeve AU -玛丽Machulda AU -罗纳德·彼得森Y1 - 2015/04/06 UR - //www.ez-admanager.com/content/84/14_Supplement/S41.007.abstract N2 -目的:定义的角色β-amyloidosis在大脑皮层结构和功能的零星的轻度认知障碍(MCI)阶段晚发型阿尔茨海默病(AD)。背景:即使β-amyloidosis不是认知障碍的近因零星的迟发性的广告,β-amyloid一旦开始认知障碍可以促进其他神经退化过程。设计/方法:我们检查了60 MCI和115认知正常的梅奥诊所(CN)的参与者老化或梅奥阿兹海默氏症研究中心,是在70年,并且生串行成像生物标志物。参与者被描述为有异常或正常的大脑β-amyloidosis(+或-)基于11 c-pittsburgh复合B正电子发射断层扫描(PET),和N + N -基于异常低的海马体积或代谢减退fluoro-deoxyglucose 18日广告模式(FDG) PET。我们检查了地区先生和FDG PET变化+ / N +和- / N +组。结果:FDG比率下降的内侧和外侧颞区域MCI + / N +组相比,MCI - / N +集团“N +”的定义是否只由一个或其他神经退化成像方法。岛,内侧壁和侧顶叶下降MCI + / N +被认为在一些分析。体积纵向差异MCI + / N +, MCI - / N +仅限于内侧或外侧颞区域。β-amyloidosis与更大的代谢和结构变化在MCI isocortex比CN + / N + N + / +。没有结构或代谢模式是独特的MCI - / N +。 CONCLUSIONS: β-amyloidosis was associated with greater metabolic declines and volume losses in temporal and parietal isocortical regions in persons with MCI. Study Support: NIH grants P50 AG16574, U01 AG06786, R01 AG11378, Elsie and Marvin Dekelboum Family Foundation, Robert H. and Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program of the Mayo FoundationDisclosure: Neurology, Deputy Editor, Dr. Jack has received personal compensation for activities with Janssen Pharmaceuticals as a consultant. Dr. Jack has received research support from the National Institutes of Health. Dr. Lundt has nothing to disclose. Dr. Wiste has nothing to disclose. Dr. Weigand has nothing to disclose. Dr. Vemuri has nothing to disclose. Dr. Lowe has received personal compensation for activities with Bayer Pharmaceuticals as a consultant. Dr. Kantarci has nothing to disclose. Dr. Gunter has nothing to disclose. Dr. Senjem has nothing to disclose. Dr. Mielke has nothing to disclose. Dr. Roberts has nothing to disclose. Dr. Boeve has received research support from GE Healthcare. Dr. Machulda has nothing to disclose. Dr. Petersen has received personal compensation for activities with Pfizer Inc. and Janssen Alzheimer's Immunotherapy.Thursday, April 23 2015, 1:00 pm-2:45 pm ER -